139 related articles for article (PubMed ID: 30986302)
21. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers.
Coda BA; Rudy AC; Archer SM; Wermeling DP
Anesth Analg; 2003 Jul; 97(1):117-23, table of contents. PubMed ID: 12818953
[TBL] [Abstract][Full Text] [Related]
22. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
[TBL] [Abstract][Full Text] [Related]
23. A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers.
Rudy AC; Coda BA; Archer SM; Wermeling DP
Anesth Analg; 2004 Nov; 99(5):1379-1386. PubMed ID: 15502034
[TBL] [Abstract][Full Text] [Related]
24. Single-dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate-release and hydrophilic matrix extended-release tablets in healthy Japanese subjects without co-administration of an opioid antagonist.
Toyama K; Uchida N; Ishizuka H; Sambe T; Kobayashi S
J Clin Pharmacol; 2015 Sep; 55(9):975-84. PubMed ID: 25807927
[TBL] [Abstract][Full Text] [Related]
25. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER.
Webster LR; Pantaleon C; Shah MS; DiFalco R; Iverson M; Smith MD; Kinzler ER; Aigner S
Pain Med; 2017 Jul; 18(7):1303-1313. PubMed ID: 27651506
[TBL] [Abstract][Full Text] [Related]
26. Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.
Webster L; Henningfield J; Buchhalter AR; Siddhanti S; Lu L; Odinecs A; Di Fonzo CJ; Eldon MA
Pain Med; 2018 Feb; 19(2):307-318. PubMed ID: 28340145
[TBL] [Abstract][Full Text] [Related]
27. Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Darwish M; Bond M; Ma Y; Tracewell W; Robertson P; Webster LR
Pain Med; 2017 Jan; 18(1):61-77. PubMed ID: 27330154
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
Meske D; Kopecky EA; Passik S; Shram MJ
J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic and Pharmacodynamic Correlations From 2 Studies Evaluating Abuse Potential of Hydrocodone Extended-Release Tablets.
Schoedel KA; Gillespie M; Levy-Cooperman N; Shram MJ; Rabinovich-Guilatt L
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):32-39. PubMed ID: 29723441
[TBL] [Abstract][Full Text] [Related]
30. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
31. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
Setnik B; Sommerville K; Goli V; Han L; Webster L
Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food.
Sathyan G; Xu E; Thipphawong J; Gupta SK
BMC Clin Pharmacol; 2007 Feb; 7():2. PubMed ID: 17270055
[TBL] [Abstract][Full Text] [Related]
33. Dose proportionality and pharmacokinetics of extended-release (OROS®) hydromorphone: a phase 1, open-label, randomized, crossover study in healthy Taiwanese subjects.
Vandenbossche J; Richards HM; Lu CC; Richarz U
Int J Clin Pharmacol Ther; 2014 Mar; 52(3):217-26. PubMed ID: 24472398
[TBL] [Abstract][Full Text] [Related]
34. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
[TBL] [Abstract][Full Text] [Related]
35. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.
Smith MD; Webster LR; Lawler J; Lindhardt K; Dayno JM
Pain Med; 2017 May; 18(5):898-907. PubMed ID: 27633773
[TBL] [Abstract][Full Text] [Related]
36. Dose proportionality of the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR).
Durnin C; Hind ID; Ghani SP; Yates DB; Cross M
Proc West Pharmacol Soc; 2001; 44():73-4. PubMed ID: 11794000
[No Abstract] [Full Text] [Related]
37. Correlation of Subjective Effects with Systemic Opioid Exposure from Fixed-Dose Combinations of Oxycodone/Acetaminophen in Recreational Users of Prescription Drugs.
Morton TL; Devarakonda K; Kostenbader K; Montgomery J; Barrett T; Webster L
Pain Med; 2016 Mar; 17(3):539-550. PubMed ID: 26304767
[TBL] [Abstract][Full Text] [Related]
38. Effect of food on the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR).
Durnin C; Hind ID; Channon E; Yates DB; Cross M
Proc West Pharmacol Soc; 2001; 44():75-6. PubMed ID: 11794001
[No Abstract] [Full Text] [Related]
39. Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
Kinzler ER; Pantaleon C; Aigner S
Clin Ther; 2018 Aug; 40(8):1357-1365. PubMed ID: 30049503
[TBL] [Abstract][Full Text] [Related]
40. Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study.
Pathak S; Vince B; Kelsh D; Setnik B; Nangia N; DiPetrillo L; Puhl MD; Sun L; Stanford AD; Ehrich E
J Clin Pharmacol; 2019 Feb; 59(2):218-228. PubMed ID: 30476361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
